CLAIMS

1. A method of treating steroid-dependent disease in a subject in need thereof, comprising administering a therapeutically effective amount a CYP17A inhibitor and an effective amount of a 5-α-reductase inhibitor to the subject.

2. The method of claim 1, wherein the steroid-dependent disease is steroid-dependent cancer.

3. The method of claim 2, wherein the cancer is prostate cancer.

4. The method of claim 3, wherein the prostate cancer is castration-resistant prostate cancer.

5. The method of claim 1, wherein the CYP17A inhibitor is selected from the group consisting of abiraterone, the abiraterone metabolite D4A, and galeterone.

6. The method of claim 1, wherein the CYP17A inhibitor is selected from the group consisting of abiraterone and the abiraterone metabolite D4A.

7. The method of claim 1, further comprising the step of modifying treatment by determining the level of one or more CYP17A inhibitor metabolites in a biological sample from the subject.

8. The method of claim 7, wherein the CYP17A inhibitor is abiraterone, and the CYP17A inhibitor metabolites are selected from the group consisting of D4A, 3β-OH-5β-abi, 3-keto-5α-abi, 3-keto-5β-abi, 3α-OH-5α-abi, 3α-OH-5β-abi, and 3β-OH-5α-abi.

9. The method of claim 1, wherein the 5-α-reductase inhibitor is selected from the group consisting of dutasteride, finasteride, lapisteride, turosteride, bexlosteride, izonsteride, and epristeride.

10. The method of claim 1, wherein CYP17A inhibitor and the 5-α-reductase inhibitor are administered with a pharmaceutically acceptable carrier.

11. The method of claim 1, wherein one or more of the CYP17A inhibitor and/or the 5-α-reductase inhibitor are administered orally.

CLAIMS

1. A formulation combination for use in treatment of steroid-dependent disease in a subject in need thereof, wherein the formulation combination comprises a first formulation containing a therapeutically effective amount of a CYP17A inhibitor and a second formulation containing an effective amount of a 5-α-reductase inhibitor.

2. The formulation combination of claim 1, wherein the steroid-dependent disease is steroid-dependent cancer.

3. The formulation combination of claim 1, wherein the steroid-dependent disease is prostate cancer.

4. The formulation combination of claim 1, wherein the CYP17A inhibitor is selected from the group consisting of abiraterone, abiraterone metabolite D4A, and galeterone.

5. The formulation combination of claim 1, wherein the CYP17A inhibitor is selected from the group consisting of abiraterone and abiraterone metabolite D4A.

6. The formulation combination of claim 1, wherein the 5-α-reductase inhibitor is selected from the group consisting of dutasteride, finasteride, lapisteride, turosteride, bexlosteride, izonsteride, and epristeride.

7. The formulation combination of claim 1, wherein the formulation combination further comprises a pharmaceutically acceptable carrier.

8. The formulation combination of claim 1, wherein the first formulation is an oral formulation, and/or the second formulation is an oral formulation.

9. Use of the formulation combination of claim 1 in the manufacture of a medicament for treating steroid-dependent disease in a subject in need thereof.

10. A composition for use in treatment of steroid-dependent disease in a subject in need thereof, wherein the composition comprises a therapeutically effective amount of a CYP17A inhibitor and an effective amount of a 5-α-reductase inhibitor.

11. The composition of claim 10, wherein the steroid-dependent disease is steroid-dependent cancer.

12. The composition of claim 10, wherein the steroid-dependent disease is prostate cancer.

13. The composition of claim 10, wherein the CYP17A inhibitor is selected from the group consisting of abiraterone, abiraterone metabolite D4A, and galeterone.

14. The composition of claim 10, wherein the CYP17A inhibitor is selected from the group consisting of abiraterone and abiraterone metabolite D4A.

15. The composition of claim 10, wherein the 5-α-reductase inhibitor is selected from the group consisting of dutasteride, finasteride, lapisteride, turosteride, bexlosteride, izonsteride, and epristeride.

16. The composition of claim 10, wherein the composition further comprises a pharmaceutically acceptable carrier.

17. The composition of claim 10, wherein the composition is an oral formulation.

18. Use of the composition of claim 10 in the manufacture of a medicament for treating steroid-dependent disease in a subject in need thereof.